Join us at SLAS Barcelona

Festo LifeTech is exhibiting at the SLAS in Barcelona.

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Så går det i kapplöpningen mellan de nya alzheimerläkemedlen Kisunla och Leqembi

Kisunla eller Leqembi? Konkurrensen mellan Eli Lilly och Bioartic fortsätter. Där konkurrenten får godkänt går den andre bet. Här läser du vilka marknader som d...

IVDR Reality Check: Are We Moving Fast Enough?

As of February 2025, around 1,500 IVDR certificates have been issued. But if an estimated 18,700 devices still need certification before the 2029 deadline, then...

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

ProPharma

Wegovy approved in the U.S. for treatment of liver disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Snabbtest för halsfluss gav 40 procent falskt positiva svar

Ett snabbtest mot halsfluss har visat sig ge en mycket hög andel falskt positiva svar. Nu uppmanar företaget bakom testet vårdgivare att kassera berörda partier av produkten.

Vykat XR – ny pillerbehandling mot omåttlig aptit

FDA har godkänt den första behandlingen för en genetisk störning som bland annat präglas av omåttlig aptit.

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2026)

Pfizer Health AB, Site Strängnäs

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

Cancerforskaren: ”Vi kan göra mer och minska lidandet”

Lundaforskaren Catharina Hagerling utvecklar metoder för att förstå metastaserad cancer, med målet att skapa mer riktade behandlingar för patienter med spridd cancer

Karriärcoachen: Så får du AI att söka jobbet åt dig

För att använda AI effektivt måste vi ändra vårt tankesätt för hur vi kommunicerar. Annars får vi bara döda motivationsbrev och döda resuméer. Det anser karriär...

Rekordstor donation till cancerforskning i Lund – ”Once in a lifetime-möjlighet”

Lunds universitet får den största donationen i lärosätets moderna historia, enligt ett pressmeddelande.

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...